10x Genomics to Report Third Quarter Financial Results on November 2, 2022
10x Genomics (Nasdaq: TXG) will announce its third quarter 2022 financial results after market close on November 2, 2022. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. Investors can access the live audio on the company's website, with playback available for at least 45 days post-event. 10x Genomics provides advanced life science technology solutions for analyzing biological systems, with strong adoption among leading global research institutions and pharmaceutical companies.
- Strong adoption of products by top 100 global research institutions and top 20 pharmaceutical companies.
- Over 3,800 citations in research papers showcasing company’s impact on oncology, immunology, and neuroscience.
- None.
PLEASANTON, Calif., Oct. 12, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 3,800 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,500 issued patents and patent applications.
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-third-quarter-financial-results-on-november-2-2022-301647846.html
SOURCE 10x Genomics, Inc.
FAQ
When will 10x Genomics report its Q3 2022 earnings?
What time is the 10x Genomics Q3 2022 earnings conference call?
How can I listen to the 10x Genomics earnings call?
What is the business focus of 10x Genomics?
